Induction of IgM, IgA and IgE antibodies in colorectal cancer patients vaccinated with a recombinant CEA protein

Journal of Clinical Immunology

Volumn 32, Issue 4, 2012, Pages 855-865

  Staff, Caroline ^a   Magnusson, Carl G M ^b   Hojjat Farsangi, Mohammad ^a   Mosolits, Szilvia ^a   Liljefors, Maria ^a   Frödin, Jan Erik ^a   Wahrén, Britta ^c   Mellstedt, Hakan ^a   Ullenhag, Gustav J ^d  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Karolinska University Hospital   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

ADCC; CDC; CEA; Colorectal cancer; GM CSF; IgA; Vaccination

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; RECOMBINANT CARCINOEMBRYONIC ANTIGEN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG DOSE COMPARISON; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; LOW DRUG DOSE; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; APOPTOSIS; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; VACCINATION; VACCINES, SYNTHETIC;

EID: 84863988579     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-012-9662-7     Document Type: Article

References (43)

1. Baseler MW, Maxim PE, Veltri RW. Circulating IgA immune complexes in head and neck cancer, nasopharyngeal carcinoma, lung cancer, and colon cancer. Cancer. 1987;59:1727-31. (Pubitemid 17075418)
2. Brandlein S, Lorenz J, Ruoff N, Hensel F, Beyer I, Muller J, Neukam K, Illert B, Eck M, Muller-Hermelink HK, et al. Human monoclonal IgM antibodies with apoptotic activity isolated from cancer patients. Hum Antibodies. 2002;11:107-19. (Pubitemid 36470163)
3. Brandlein S, Pohle T, Ruoff N, Wozniak E, Muller-Hermelink HK, Vollmers HP. Natural IgM antibodies and immunosurveillance mechanisms against epithelial cancer cells in humans. Cancer Res. 2003;63:7995-8005. (Pubitemid 37466738)
4. Gould HJ, Mackay GA, Karagiannis SN, O'Toole CM, Marsh PJ, Daniel BE, Coney LR, Zurawski Jr VR, Joseph M, Capron M, et al. Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma. Eur J Immunol. 1999;29:3527-37. (Pubitemid 29527800)
5. Julien S, Picco G, Sewell R, Vercoutter-Edouart AS, Tarp M, Miles D, Clausen H, Taylor-Papadimitriou J, Burchell JM. Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine model. Br J Cancer. 2009;100:1746-54.
6. Karagiannis SN, Bracher MG, Hunt J, McCloskey N, Beavil RL, Beavil AJ, Fear DJ, Thompson RG, East N, Burke F, et al. IgEantibody- dependent immunotherapy of solid tumors: Cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells. J Immunol. 2007;179:2832-43.
7. Albanopoulos K, Armakolas A, Konstadoulakis MM, Leandros E, Tsiompanou E, Katsaragakis S, Alexiou D, Androulakis G. Prognostic significance of circulating antibodies against carcinoembryonic antigen (anti-CEA) in patients with colon cancer. Am J Gastroenterol. 2000;95:1056-61. (Pubitemid 30196746)
8. Livingston PO, Wong GY, Adluri S, Tao Y, Padavan M, Parente R, Hanlon C, Calves MJ, Helling F, Ritter G, et al. Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol. 1994;12:1036-44. (Pubitemid 24145334)
9. Beutner U, Lorenz U, Illert B, Rott L, TimmermannW, Vollmers HP, Muller-Hermelink HK, Thiede A, Ulrichs K. Neoadjuvant therapy of gastric cancer with the human monoclonal IgM antibody SC-1: Impact on the immune system. Oncol Rep. 2008;19:761-9. (Pubitemid 351336879)
10. Riemer AB, Untersmayr E, Knittelfelder R, Duschl A, Pehamberger H, Zielinski CC, Scheiner O, Jensen-Jarolim E. Active induction of tumor-specific IgE antibodies by oral mimotope vaccination. Cancer Res. 2007;67:3406-11. (Pubitemid 46724881)
11. Dechant M, Valerius T. IgA antibodies for cancer therapy. Crit Rev Oncol Hematol. 2001;39:69-77. (Pubitemid 32564867)
12. Ullenhag GJ, Frodin JE, Jeddi-Tehrani M, Strigard K, Eriksson E, Samanci A, Choudhury A, Nilsson B, Rossmann ED, Mosolits S, et al. Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor. Clin Cancer Res. 2004;10:3273-81. (Pubitemid 38685431)
13. Ullenhag GJ, Frodin JE, Strigard K, Mellstedt H, Magnusson CG. Induction of IgG subclass responses in colorectal carcinoma patients vaccinated with recombinant carcinoembryonic antigen. Cancer Res. 2002;62:1364-9. (Pubitemid 34407793)
14. Kass E, Panicali DL,Mazzara G, Schlom J, Greiner JW. Granulocyte/ macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res. 2001;61:206-14. (Pubitemid 32095719)
15. Abe J, Wakimoto H, Yoshida Y, Aoyagi M, Hirakawa K, Hamada H. Antitumor effect induced by granulocyte/macrophage-colonystimulating factor gene-modified tumor vaccination: Comparison of adenovirus- and retrovirus-mediated genetic transduction. J Cancer Res Clin Oncol. 1995;121:587-92.
16. Samanci A, Yi Q, Fagerberg J, Strigard K, Smith G, Ruden U, Wahren B, Mellstedt H. Pharmacological administration of granulocyte/macrophage-colony- stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen. Cancer Immunol Immunother. 1998;47:131-42. (Pubitemid 28518327)
17. Oikawa S, Nakazato H, Kosaki G. Primary structure of human carcinoembryonic antigen (CEA) deduced from cDNA sequence. Biochem Biophys Res Commun. 1987;142:511-8. (Pubitemid 17003376)
18. Schrewe H, Thompson J, Bona M, Hefta LJ, Maruya A, Hassauer M, Shively JE, von Kleist S, Zimmermann W. Cloning of the complete gene for carcinoembryonic antigen: Analysis of its promoter indicates a region conveying cell type-specific expression. Mol Cell Biol. 1990;10:2738-48.
19. Bjorklund JE, Stibler H, Kristiansson B, Johansson SG, Magnusson CG. Immunoglobulin levels in patients with carbohydratedeficient glycoprotein syndrome type I. Int Arch Allergy Immunol. 1997;114:116-9. (Pubitemid 27397065)
20. Magnusson CG, Nelson DF, Magnusson MA. Disproportional distribution of isotype and non-isotype-specific IgG subclass anti-IgE autoantibodies in human cord serum. Int Arch Allergy Immunol. 1996;110:31-40. (Pubitemid 26116030)
21. Bruggemann M, Williams GT, Bindon CI, Clark MR, Walker MR, Jefferis R, Waldmann H, Neuberger MS. Comparison of the effector functions of human immunoglobulins using amatched set of chimeric antibodies. J Exp Med. 1987;166:1351-61. (Pubitemid 18051427)
22. Daneshmanesh AH, Mikaelsson E, Jeddi-Tehrani M, Bayat AA, Ghods R, Ostadkarampour M, Akhondi M, Lagercrantz S, Larsson C, Osterborg A, et al. Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy. Int J Cancer. 2008;123:1190-5.
23. Teeling JL, French RR, CraggMS, van den Brakel J, Pluyter M, Huang H, Chan C, Parren PW, Hack CE, DechantM, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. 2004;104:1793-800. (Pubitemid 39202289)
24. Liljefors M, Nilsson B, Mellstedt H, Frodin JE. Influence of varying doses of granulocyte-macrophage colony-stimulating factor on pharmacokinetics and antibody-dependent cellular cytotoxicity. Cancer Immunol Immunother. 2008;57:379-88. (Pubitemid 350295379)
25. Frodin JE, Faxas ME, Hagstrom B, Lefvert AK, Masucci G, Nilsson B, Steinitz M, Unger P, Mellstedt H. Induction of anti-idiotypic (ab2) and anti-anti-idiotypic (ab3) antibodies in patients treated with the mouse monoclonal antibody 17-1A (ab1). Relation to the clinical outcome-an important antitumoral effector function? Hybridoma. 1991;10:421-31.
26. Enterline PE. Pitfalls in epidemiological research. An examination of the asbestos literature. J Occup Med. 1976;18:150-6.
27. Kalblfeisch J, Prentice R-L. Time dependant covariates and further remarks on likelihood construction. The statistical analysis of failure time data, John Wiley and sons, New York 1st ed. 1980;122-142.
28. Mota G, Manciulea M, Cosma E, Popescu I, Hirt M, Jensen- Jarolim E, Calugaru A, Galatiuc C, Regalia T, Tamandl D, et al. Human NK cells express Fc receptors for IgA which mediate signal transduction and target cell killing. Eur J Immunol. 2003;33:2197-205. (Pubitemid 37010037)
29. Huls G, Heijnen IA, Cuomo E, van der Linden J, Boel E, van de Winkel JG, Logtenberg T. Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies. Cancer Res. 1999;59:5778-84.
30. Dechant M, Vidarsson G, Stockmeyer B, Repp R, Glennie MJ, Gramatzki M, van De Winkel JG, Valerius T. Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. Blood. 2002;100:4574-80. (Pubitemid 35429700)
31. Roos A, Bouwman LH, van Gijlswijk-Janssen DJ, Faber-Krol MC, Stahl GL, DahaMR. Human IgA activates the complement systemvia the mannan-binding lectin pathway. J Immunol. 2001;167:2861-8. (Pubitemid 32768920)
32. Hiemstra PS, Gorter A, Stuurman ME, Van Es LA, Daha MR. Activation of the alternative pathway of complement by human serum IgA. Eur J Immunol. 1987;17:321-6. (Pubitemid 17060784)
33. Vollmers HP, Zimmermann U, Krenn V, Timmermann W, Illert B, Hensel F, Hermann R, Thiede A, Wilhelm M, Ruckle-Lanz H, et al. Adjuvant therapy for gastric adenocarcinoma with the apoptosis-inducing human monoclonal antibody SC-1: first clinical and histopathological results. Oncol Rep. 1998;5:549-52. (Pubitemid 28189303)
34. Karagiannis SN, Bracher MG, Beavil RL, Beavil AJ, Hunt J, McCloskey N, Thompson RG, East N, Burke F, Sutton BJ, et al. Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells. Cancer Immunol Immunother. 2008;57:247-63. (Pubitemid 350159926)
35. Kershaw MH, Darcy PK, Trapani JA, MacGregor D, Smyth MJ. Tumor-specific IgE-mediated inhibition of human colorectal carcinoma xenograft growth. Oncol Res. 1998;10:133-42. (Pubitemid 128736309)
36. Reali E, Greiner JW, Corti A, Gould HJ, Bottazzoli F, Paganelli G, Schlom J, Siccardi AG. IgEs targeted on tumor cells: Therapeutic activity and potential in the design of tumor vaccines. Cancer Res. 2001;61:5517-22. (Pubitemid 32694936)
37. Luiten RM, Fleuren GJ, Warnaar SO, Litvinov SV. Target-specific activation of mast cells by immunoglobulin E reactive with a renal cell carcinoma-associated antigen. Lab Invest. 1996;74:467-75. (Pubitemid 26072087)
38. Nakatsura T, Senju S, Ito M, Nishimura Y, Itoh K. Cellular and humoral immune responses to a human pancreatic cancer antigen, coactosin-like protein, originally defined by the SEREX method. Eur J Immunol. 2002;32:826-36. (Pubitemid 34257560)
39. Carr A, Rodriguez E, Arango Mdel C, Camacho R, Osorio M, Gabri M, Carrillo G, Valdes Z, Bebelagua Y, Perez R, et al. Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine. J Clin Oncol. 2003;21:1015-21. (Pubitemid 46594129)
40. Ragupathi G, Livingston PO, Hood C, Gathuru J, Krown SE, Chapman PB, Wolchok JD, Williams LJ, Oldfield RC, Hwu WJ. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin Cancer Res. 2003;9:5214-20. (Pubitemid 37413571)
41. Gilewski TA, Ragupathi G, Dickler M, Powell S, Bhuta S, Panageas K, Koganty RR, Chin-Eng J, Hudis C, Norton L, et al. Immunization of high-risk breast cancer patients with clustered sTn- KLH conjugate plus the immunologic adjuvant QS-21. Clin Cancer Res. 2007;13:2977-85. (Pubitemid 46849573)
42. Rieser C, Ramoner R, Holtl L, Rogatsch H, Papesh C, Stenzl A, Bartsch G, Thurnher M. Mature dendritic cells induce T-helper type-1-dominant immune responses in patients with metastatic renal cell carcinoma. Urol Int. 1999;63:151-9. (Pubitemid 30083819)
43. Miyagi Y, Imai N, Sasatomi T, Yamada A, Mine T, Katagiri K, Nakagawa M, Muto A, Okouchi S, Isomoto H, et al. Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides. Clin Cancer Res. 2001;7:3950-62. (Pubitemid 34044613)